{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:14:48Z","timestamp":1790486088052,"version":"4.1.0"},"reference-count":40,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Background and objective: Pain is a frequent and disabling symptom in Parkinson\u2019s disease (PD) patients. Our aim was to analyze the effectiveness of safinamide on pain in PD patients from the SAFINONMOTOR (an open-label study of the effectiveness of SAFInamide on NON-MOTOR symptoms in Parkinson\u00b4s disease patients) study. Material and Methods: SAFINONMOTOR is a prospective open-label single-arm study conducted in five centers from Spain. In this analysis, a secondary objective of the study, the score in the KPPS (King\u00b4s Parkinson\u00b4s Disease Pain Scale) at V1 (baseline) and V4 (6 months \u00b1 1 month) were compared. Wilcoxon\u00b4s rank sum test was performed to test the changes from V1 to V4. Results: Forty-four (88%) out of 50 PD patients (age 68.5 \u00b1 9.12 years; 58% women; 6.4 \u00b1 5.1 years from diagnosis) completed the study. The KPPS total score was reduced by 43.6% (from 40.04 \u00b1 36.18 in V1 to 22.60 \u00b1 21.42 in V4; p &lt; 0.0001). By domains, improvement was observed in musculoskeletal (\u221235.9%; p = 0.009), fluctuation-related (\u221251.7%; p = 0.020), nocturnal (\u221246.1%; p = 0.001), discoloration and\/or edema\/swelling (\u221250.4%; p = 0.009) and radicular pain (\u221240.1%; p = 0.048). A total of 21 adverse events in 11 patients (22%) were reported, five being severe, but not related to safinamide. Conclusion: Safinamide is well tolerated and improves pain in PD patients at 6 months. Future studies are necessary to analyze the possible beneficial effect of safinamide on pain in PD patients.<\/jats:p>","DOI":"10.3390\/jpm11080798","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T21:27:45Z","timestamp":1629149265000},"page":"798","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Pain Improvement in Parkinson\u2019s Disease Patients Treated with Safinamide: Results from the SAFINONMOTOR Study"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-5111","authenticated-orcid":false,"given":"Diego","family":"Santos Garc\u00eda","sequence":"first","affiliation":[{"name":"Department of Neurology, CHUAC, Complejo Hospitalario Universitario de A Coru\u00f1a, 15006 A Coru\u00f1a, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Y\u00e1\u00f1ez Ba\u00f1a","sequence":"additional","affiliation":[{"name":"Department of Neurology, CHUO, Complejo Hospitalario Universitario de Ourense, 32005 Ourense, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Labandeira Guerra","sequence":"additional","affiliation":[{"name":"Department of Neurology, CHUVI, Complejo Hospitalario Universitario de Vigo, 36213 Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ic\u00edar","family":"Cimas Hernando","sequence":"additional","affiliation":[{"name":"Hospital de Povisa, 36211 Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2436-6499","authenticated-orcid":false,"given":"Iria","family":"Cabo L\u00f3pez","sequence":"additional","affiliation":[{"name":"Department of Neurology, CHOP, Complejo Hospitalario Universitario de Pontevedra, 36002 Pontevedra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Manuel","family":"Paz Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Department of Neurology, CHUAC, Complejo Hospitalario Universitario de A Coru\u00f1a, 15006 A Coru\u00f1a, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gema","family":"Alonso Losada","sequence":"additional","affiliation":[{"name":"Department of Neurology, CHUVI, Complejo Hospitalario Universitario de Vigo, 36213 Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"Gonzalez Palm\u00e1s","sequence":"additional","affiliation":[{"name":"Department of Neurology, CHOP, Complejo Hospitalario Universitario de Pontevedra, 36002 Pontevedra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8352-2263","authenticated-orcid":false,"given":"Carlos","family":"Cores Bartolom\u00e9","sequence":"additional","affiliation":[{"name":"Department of Neurology, CHUAC, Complejo Hospitalario Universitario de A Coru\u00f1a, 15006 A Coru\u00f1a, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3968-5441","authenticated-orcid":false,"given":"Cristina","family":"Mart\u00ednez Mir\u00f3","sequence":"additional","affiliation":[{"name":"Department of Neurology, CHUAC, Complejo Hospitalario Universitario de A Coru\u00f1a, 15006 A Coru\u00f1a, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson\u2019s disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.parkreldis.2012.11.009","article-title":"Pain in Parkinson disease: A review of the literature","volume":"19","author":"Fil","year":"2013","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/mds.23959","article-title":"Pain in Parkinson\u2019s disease","volume":"27","author":"Ha","year":"2012","journal-title":"Mov. Disord."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pain.2008.12.004","article-title":"Pain in Parkinson\u2019s disease: Prevalence and characteristics","volume":"141","author":"Beiske","year":"2009","journal-title":"Pain"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1002\/mds.22716","article-title":"Pain in Parkinson\u2019s disease","volume":"25","author":"Ford","year":"2010","journal-title":"Mov. Disord."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/SPC.0000000000000546","article-title":"Pain in Parkinson\u2019s disease: Mechanism-based treatment strategies","volume":"15","author":"Rukavina","year":"2021","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2174\/1570159X17666190618121859","article-title":"The Modulation of Pain by Metabotropic Glutamate Receptors 7 and 8 in the Dorsal Striatum","volume":"18","author":"Boccella","year":"2020","journal-title":"Curr. Neuropharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2217\/nmt.15.46","article-title":"Clinical pharmacology review of safinamide for the treatment of Parkinson\u2019s disease","volume":"5","author":"Fabbri","year":"2015","journal-title":"Neurodegener. Dis. Manag."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mds.25751","article-title":"Study 016 Investigators. Randomized trial of safinamide add-on to levodopa in Parkinson\u2019s disease with motor fluctuations","volume":"29","author":"Borgohain","year":"2014","journal-title":"Mov. Disord."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/mds.25961","article-title":"Study 018 Investigators","volume":"29","author":"Borgohain","year":"2014","journal-title":"Mov. Disord."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10072-018-3628-3","article-title":"Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson\u2019s disease","volume":"40","author":"Bianchi","year":"2019","journal-title":"Neurol. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Santos Garc\u00eda, D., Labandeira Guerra, C., Y\u00e1\u00f1ez Ba\u00f1a, R., Cimas Hernando, M.I., Cabo L\u00f3pez, I., Paz Gon\u00e1lez, J.M., Alonso Losada, M.G., Gonz\u00e1lez Palm\u00e1s, M.J., and Mart\u00ednez Mir\u00f3, C. (2021). Safinamide Improves Non-Motor Symptoms Burden in Parkinson\u00b4s Disease: An Open-Label Prospective Study. Brain Sci., 11.","DOI":"10.3390\/brainsci11030316"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.parkreldis.2018.06.033","article-title":"Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson\u2019s disease patients: A validated questionnaires-controlled study","volume":"57","author":"Liguori","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Pe\u00f1a, E., Borru\u00e9, C., Mata, M., Mart\u00ednez-Castrillo, J.C., Alonso-Canovas, A., Chico, J.L., L\u00f3pez-Manzanares, L., Llanero, M., Herreros-Rodr\u00edguez, J., and Esquivel, A. (2021). Impact of SAfinamide on Depressive Symptoms in Parkinson\u2019s Disease Patients (SADness-PD Study): A Multicenter Retrospective Study. Brain Sci., 11.","DOI":"10.3390\/brainsci11020232"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-L\u00f3pez, A., S\u00e1nchez-S\u00e1nchez, A., Natera-Villalba, E., Ros-Castell\u00f3, V., Beltr\u00e1n-Corbellini, \u00c1., Fanjul-Arb\u00f3s, S., Moreno, I.P., Moreno, J.L.L.-S., Castrillo, J.C.M., and Alonso-Canovas, A. (2021). SURINPARK: Safinamide for Urinary Symptoms in Parkinson\u2019s Disease. Brain Sci., 11.","DOI":"10.3390\/brainsci11010057"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00702-020-02218-7","article-title":"Effects of safinamide on pain in Parkinson\u2019s disease with motor fluctuations: An exploratory study","volume":"127","author":"Geroin","year":"2020","journal-title":"J. Neural. Transm. (Vienna)"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3233\/JPD-160911","article-title":"Effects of Safinamide on Pain in Fluctuating Parkinson\u2019s Disease Patients: A Post-Hoc Analysis","volume":"7","author":"Cattaneo","year":"2017","journal-title":"J. Parkinsons Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s12325-018-0687-z","article-title":"Long-term Efficacy of Safinamide on Parkinson\u2019s Disease Chronic Pain","volume":"35","author":"Cattaneo","year":"2018","journal-title":"Adv. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000492221","article-title":"Comprehensive Examination of Therapies for Pain in Parkinson\u2019s Disease: A Systematic Review and Meta-Analysis","volume":"51","author":"Qureshi","year":"2018","journal-title":"Neuroepidemiology"},{"key":"ref_20","first-page":"165","article-title":"Parkinson\u2019s Disease Society Brain Bank, London: Overview and research","volume":"39","author":"Daniel","year":"1993","journal-title":"J. Neural. Transm. Suppl."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1002\/mds.21844","article-title":"Diagnostic procedures for Parkinson\u2019s disease dementia: Recommendations from the movement disorder society task force","volume":"22","author":"Dubois","year":"2007","journal-title":"Mov. Disord."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/mds.26270","article-title":"King\u00b4s Parkinson\u00b4s disease pain scale, the first scale for pain in PD: An international validation","volume":"30","author":"Chaudhuri","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/art.11440","article-title":"Adult measures of pain: The McGill Pain Questionnaire (MPQ), Rheumatoid Arthritis Pain Scale (RAPS), Short Form McGill Pain Questionnaire (SF-MPQ), Verbal Descriptive Scale (VDS), Visual Analog Scale (VAS), and West Haven-Yale Multidisciplinary Pain Inventory (WHYMPI)","volume":"49","author":"Burckhardt","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/mdc3.12921","article-title":"Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide","volume":"7","author":"Schade","year":"2020","journal-title":"Mov. Disord. Clin. Pr."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Valkovic, P., Minar, M., Singliarova, H., Harsany, J., Hanakova, M., Martinkova, J., and Benetin, J. (2015). Pain in Parkinson\u2019s Disease: A Cross-Sectional Study of Its Prevalence, Types, and Relationship to Depression and Quality of Life. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0136541"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nrneurol.2012.54","article-title":"Pains in Parkinson disease\u2014Many syndromes under one umbrella","volume":"8","author":"Wasner","year":"2012","journal-title":"Nat. Rev. Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","article-title":"Non-motor symptoms of Parkinson\u2019s disease: Dopaminergic pathophysiology and treatment","volume":"8","author":"Chaudhuri","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1212\/WNL.63.8_suppl_3.S35","article-title":"Treatment of nocturnal disturbances and excessive daytime sleepiness in Parkinson\u2019s disease","volume":"63","author":"Barone","year":"2004","journal-title":"Neurology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/ene.14221","article-title":"COPPADIS Study Group. Non-motor symptom burden is strongly correlated to motor complications in patients with Parkinson\u2019s disease","volume":"27","author":"Fonticoba","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.parkreldis.2020.09.024","article-title":"Unmet needs in Parkinson disease: Motor and non-motor","volume":"80","author":"LeWitt","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/JGP.0b013e31818af7ef","article-title":"Pain and its relationship to depression in Parkinson disease","volume":"17","author":"Ehrt","year":"2009","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S226","DOI":"10.1016\/S1353-8020(11)70069-4","article-title":"Pathophysiology of pain and fatigue in Parkinson\u2019s disease","volume":"18","author":"Berardelli","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1136\/jnnp.2007.120212","article-title":"Levodopa raises objective pain threshold in Parkinson\u2019s disease: A RIII reflex study","volume":"78","author":"Thalamas","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/archneurol.2008.2","article-title":"Pain as a nonmotor symptom of Parkinson disease: Evidence from a case-control study","volume":"65","author":"Defazio","year":"2008","journal-title":"Arch. Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0304-3959(94)00172-B","article-title":"The role of the basal ganglia in nociception and pain","volume":"60","author":"Chudler","year":"1995","journal-title":"Pain"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s00415-009-0908-0","article-title":"Chronic subthalamic deep brain stimulation improves pain in Parkinson disease","volume":"255","author":"Kim","year":"2008","journal-title":"J. Neurol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/ene.14552","article-title":"Overnight switch from rasagiline to safinamide in Parkinson\u2019s disease patients with motor fluctuations: A tolerability and safety study","volume":"28","author":"Stocchi","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2147\/DDDT.S77749","article-title":"Adjuvant therapies for Parkinson\u2019s disease: Critical evaluation of safinamide","volume":"10","author":"Stocchi","year":"2016","journal-title":"Drug Des. Devel"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jns.2013.07.005","article-title":"Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson\u2019s disease","volume":"332","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/mds.28261","article-title":"Impact of Coronavirus Disease 2019 Pandemic on Parkinson\u2019s Disease: A Cross-Sectional Survey of 568 Spanish Patients","volume":"35","author":"Oreiro","year":"2020","journal-title":"Mov. Disord."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/11\/8\/798\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:47:07Z","timestamp":1760165227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/11\/8\/798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":40,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["jpm11080798"],"URL":"https:\/\/doi.org\/10.3390\/jpm11080798","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,16]]}}}